News | Radiation Therapy | February 16, 2017

Targeted Radiosurgery Better Than Whole-brain Radiation for Treating Brain Tumors

Study shows effectiveness of radiosurgery in controlling spread of brain cancer after surgery

targeted radiosurgery, stereotactic radiosurgery, whole-brain radiation, brain tumor metastases, Cureus, University of Missouri School of Medicine study

February 16, 2017 — University of Missouri (MU) School of Medicine researchers compared two common postsurgical therapies for metastatic brain tumors and found that stereotactic radiosurgery can provide better outcomes for patients compared to whole-brain radiation.

During whole-brain radiation therapy, beams of radiation cover the entire brain. Because it treats the whole brain, the therapy is thought to control the spread of tumors by treating both identifiable and hidden cancerous cells. However, whole-brain radiation has been associated with a decline in cognitive functions that can negatively affect a patient’s quality of life.

In stereotactic radiosurgery, radiation is delivered to more precise areas of the brain. Because it is a targeted therapy, less collateral damage occurs to healthy brain tissue. As a result, patients experience less cognitive decline when compared to whole-brain radiation, and experience a higher quality of life.

"Although radiosurgery has been shown to be an effective post-surgical treatment for metastatic brain tumors, previous studies did not compare patient outcomes from a single hospital over the same period of time," said N. Scott Litofsky, M.D., chief of the Division of Neurological Surgery at the MU School of Medicine and senior author of the study. "Our study is one of the first to directly compare outcomes of patients treated at the same hospital during a set period of time. Ultimately, our findings reinforce the use of radiosurgery over whole-brain radiation."

Under Litofsky’s mentorship, Kristen Scheitler-Ring, a medical student doing a pathology fellowship at the MU School of Medicine, studied the outcomes of patients treated at MU Health Care from 2010 to 2014. After undergoing brain surgery to remove a metastatic tumor, 46 patients received whole-brain radiation, while 37 patients received radiosurgery. The researchers found that radiosurgery controlled the spread of the cancerous cells as effectively as whole-brain radiation; patients who received radiosurgery experienced less cognitive decline compared to those who received whole-brain radiation. Additionally, the median survival rate for patients who received radiosurgery was 440 days, compared to 202 days for patients who received whole-brain radiation.

"For patients with metastatic cancer of the brain, the importance of surviving for a longer period of time cannot be overstated," Litofsky said. "In our practice, we now treat patients almost exclusively with radiosurgery following their surgery. Although this therapy does cost more, results often can be achieved in one to three visits compared to 10 to 12 visits for whole-brain radiation. With these considerations, we strongly suggest physicians consider radiosurgery as an initial radiation treatment after surgery."

The study, "Radiosurgery to the Postoperative Tumor Bed for Metastatic Carcinoma Versus Whole Brain Radiation after Surgery," recently was published in the medical journal Cureus. Research reported in this publication was supported by a Bob Willis Medical Student Fellowship of the American Brain Tumor Association and a Medical Student Summer Research Fellowship from the MU School of Medicine Office of Medical Research. The researchers have no conflicts of interest to declare related to this study.

For more information: www.cureus.com

References

Scheitler-Ring, K., Ge, B., Petroski, G., Biedermann, G., et al. "Radiosurgery to the Postoperative Tumor Bed for Metastatic Carcinoma Versus Whole Brain Radiation After Surgery," Cureus. Published Nov. 19, 2016. doi:10.7759/cureus.885

Related Content

Mirada Medical Releases DLCExpert for Radiotherapy Treatment Planning
Technology | Treatment Planning | February 22, 2018
February 22, 2018 — U.K.-based medical imaging software provider Mirada Medical has released DLCExpert, the first com
Mitchell Cancer Institute Selects RayStation for TomoTherapy Planning
News | Treatment Planning | February 16, 2018
The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Ala., has selected RayStation as its...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
Varian Acquires Mobius Medical Systems
News | Quality Assurance (QA) | February 06, 2018
February 6, 2018 – Varian announced it has acquired privately-held Mobius Medical Systems, a...
Microbubbles Make Breast Cancer More Susceptible to Radiation Therapy
News | Women's Health | February 01, 2018
February 1, 2018 – Injecting breast cancer with oxygen-filled microbubbles makes tumors three-times more sensitive to
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
RayStation Selected for India’s First Proton Center
News | Proton Therapy | February 01, 2018
February 1, 2018 – Apollo Hospitals, Asia´s foremost integrated healthcare provider, has selected RayStation for a ne
Varian Signs Agreement to Acquire Sirtex
News | Radiation Therapy | January 31, 2018
January 31, 2018 — Varian Medical Systems announced it has signed an agreement to acquire all the outstanding shares
RayStation Selected for London's Charing Cross Hospital and Hammersmith Hospital
News | Treatment Planning | January 30, 2018
Imperial College Healthcare NHS Trust in London, U.K., has chosen RayStation as the sole treatment planning system for...
Overlay Init